W
WAVEMAN · COMPANY
PBLS · Parabilis Medicines, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

PBLS

Parabilis Medicines, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001657677
CLUSTER · 4 INSIDERSACTIVIST 13D☆ WATCH
INSIDER NET · 180D
$441.4M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
4
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
80
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
11
codes C/M, not in net · $5.0M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$441.4M over 180 days
+$441.4M over 90 days · +$440.7M of it by a 10%+ holder
the highest in Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
80 funds added or opened last quarter
more than 57% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
12.8 days to cover · settled 2026-07-31
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
4 insiders independently bought a net $441.4M — no planned sales are queued against it.
80 funds added or opened positions in the latest 13F quarter, of 80 holders.
RA Capital Management, L.P. disclosed a 5%+ stake (23.8%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +26.9%
+26.9%12M
-21%-4%+14%+31%2026-062026-062026-072026-072026-082026-082026-08 2026-06-11 · RA Capital Nexus Fund III, L.P. bought $394.6M2026-06-11 · RA Capital Nexus Fund III, L.P. bought $29.2M2026-06-11 · Soleus Capital Group, LLC bought $7.5M2026-07-20 · RA CAPITAL MANAGEMENT, L.P. bought $2.7M2026-06-11 · Soleus Capital Group, LLC bought $2.5M2026-07-22 · RA CAPITAL MANAGEMENT, L.P. bought $1.4M2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $1.1M2026-07-20 · RA CAPITAL MANAGEMENT, L.P. bought $914.4K2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $606.6K2026-06-11 · SEBULSKY ALAN bought $250.0K2026-06-12 · SEBULSKY ALAN bought $233.4K2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $189.7K2026-06-15 · SEBULSKY ALAN bought $130.0K2026-06-15 · SEBULSKY ALAN bought $110.2K2026-06-18 · RA Capital Management, L.P. filed a 5%+ stake (23.8%)2026-06-18 · Peter Kolchinsky filed a 5%+ stake (23.8%)2026-06-18 · Rajeev Shah filed a 5%+ stake (23.8%)2026-06-18 · RA Capital Healthcare Fund, L.P. filed a 5%+ stake (21.6%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
4 insiders reported buying shares.
The record shows a net $441.4M bought by insiders over 180 days, 80 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Parabilis Medicines, Inc. insiders bought a net $441.4M of stock across 14 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22
47,250.0
$1.4M
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-21
21,696.0
$606.6K
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-21
6,504.0
$189.7K
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-21
37,723.0
$1.1M
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-20
98,433.0
$2.7M
14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
28,933,371.0 sh
$791.9M
FMR LLC
10,292,735.0 sh
$281.7M
ARCH Venture Management, LLC
6,412,780.0 sh
$175.5M
venBio Partners LLC
5,266,697.0 sh
$144.1M
Alphabet Inc.
4,919,498.0 sh
$134.6M
5%+ owners
13D = intent to influence · 13G = passive
RA Capital Management, L.P.
ACTIVIST 13D · 2026-06-18
23.8%
Peter Kolchinsky
ACTIVIST 13D · 2026-06-18
23.8%
Rajeev Shah
ACTIVIST 13D · 2026-06-18
23.8%
RA Capital Healthcare Fund, L.P.
ACTIVIST 13D · 2026-06-18
21.6%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
1
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →